Torthaí cuardaigh - Chris Venner
- 1 - 3 toradh as 3 á dtaispeáint
-
1
A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment de réir Mark Warren, Peter Venner, Scott North, Tina Cheng, Chris Venner, Sunita Ghosh, Allison A. Venner, Daygen L. Finch
Foilsithe / Cruthaithe 2013Artigo -
2
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III) de réir Arnaud Jaccard, Raymond L. Comenzo, Parameswaran Hari, Philip N. Hawkins, Murielle Roussel, Pierre Morel, M. Macro, Jean‐Luc Pellegrin, Estibaliz Lazaro, Dania Mohty, P. Mercié, O. Decaux, JD Gillmore, David Lavergne, Frank Bridoux, Ashutosh Wechalekar, Chris Venner
Foilsithe / Cruthaithe 2014Artigo -
3
Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROM... de réir Raymond L. Comenzo, Giovanni Palladini, Efstathios Kastritis, Monique C. Minnema, Ashutosh Wechalekar, Arnaud Jaccard, Angela Dispenzieri, Hans C. Lee, Vaishali Sanchorawala, Simon Gibbs, Peter Mollee, Chris Venner, Jin Lu, Stefan Schönland, Moshe E. Gatt, Kenshi Suzuki, Kihyun Kım, María Teresa Cibeira, Meral Beksaç, Edward N. Libby, Jason Valent, Vânia Hungria, Sandy W. Wong, Michael Rosenzweig, Naresh Bumma, NamPhuong Tran, Xiang Qin, Samer K. Khaled, Jessica Vermeulen, Giampaolo Merlini
Foilsithe / Cruthaithe 2021Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Internal medicine
Medicine
AL amyloidosis
Amyloidosis
Antibody
Bortezomib
Chemotherapy
Cohort
Cyclophosphamide
Dexamethasone
Immunoglobulin light chain
Immunology
Multiple myeloma
Oncology
Surgery
Andromeda
Cancer
Daratumumab
Dermatology
Environmental health
Galaxy
Kidney
Kidney cancer
Melphalan
Milky Way
Nephrectomy
Phases of clinical research
Physics
Population
Proportional hazards model